NCT05963386View on ClinicalTrials.gov

Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

September 15, 2024

Study Completion Date

October 5, 2024

Conditions
Refractory Solid Tumor
Interventions
DRUG

177Lu-DOTA-EB-FAPI radionuclide therapy

radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.3 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.

Trial Locations (1)

361000

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER